New pill shows promise for Hard-to-Treat cancers
NCT ID NCT05287399
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor response, but this is a very early step to see if the drug is safe enough for further testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
California Cancer Associates for Research & Excellence (cCARE)
Encinitas, California, 92024, United States
-
California Cancer Associates for Research & Excellence (cCARE)
Fresno, California, 93720, United States
-
California Cancer Associates for Research & Excellence (cCARE)
San Marcos, California, 92069, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?